Pricing Log in Create free account

Gyre Therapeutics, Inc. (GYRE) vs Valneva SE Sponsored ADR (VALN)

Gyre Therapeutics, Inc. and Valneva SE Sponsored ADR are both Biotechnology companies. Gyre Therapeutics, Inc. and Valneva SE Sponsored ADR are of similar size ($538.4M and $493.1M). Gyre Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Valneva SE Sponsored ADR trades at 63.0×. Gyre Therapeutics, Inc. grew revenue faster over the last twelve months: 13.5% against −53.2%. Valneva SE Sponsored ADR has the higher net margin (−12.0% vs −21.5%) and the higher return on invested capital (0.00% vs −8.51%). Across the 18 metrics below, Gyre Therapeutics, Inc. leads on 10 and Valneva SE Sponsored ADR on 8.

Valuation

Metric GYRE VALN Biotechnology median
P/E n/m 62.98 10.85
P/S 4.05 3.21 9.49
P/B 3.41 5.59 2.18
Price to free cash flow n/m n/m 25.85
EV/EBITDA n/m 44.98 0.70
EV/Sales 3.48 3.66 8.99
Earnings yield (6.03%) 1.59% (31.76%)
Free cash flow yield (5.15%) (11.17%) (21.84%)

Profitability

Metric GYRE VALN Biotechnology median
Gross margin 91.71% 38.28% 68.51%
Operating margin 0.00% 13.56% 0.00%
Net margin (21.46%) (12.01%) 0.00%
Free cash flow margin (19.94%) 0.00% 0.00%
Return on equity (18.54%) 0.00% (50.82%)
Return on assets (14.49%) 0.00% (46.04%)
Return on invested capital (8.51%) 0.00% 0.00%

Growth

Metric GYRE VALN Biotechnology median
Revenue growth (TTM) 13.51% (53.16%) 6.96%
EPS growth (last fiscal year) (60.00%) (805.88%) 29.88%
Revenue growth, 5-year CAGR 40.96% 9.41% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GYRE VALN Biotechnology median
Debt to equity 0.00 2.27 0.00
Current ratio 4.32 2.16 4.84
Net debt to EBITDA (3.74) (1.15) 1.01

Dividend

Metric GYRE VALN Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric GYRE VALN Biotechnology median
Market cap 493.06m 538.44m 163.56m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack